Introduction
Multiple efforts to understand glycogen storage disease type II (GSD-II) have been made in the past 70 years since the Dutch pathologist JC Pompe first described the disease in 1932. 1 Pompe disease, acid maltase deficiency or GSD-II, is an autosomal recessive disease resulting from the deficient expression of the lysosomally targeted enzyme, acid-alpha glucosidase (GAA). 2, 3 This enzyme defect leads to massive amounts of intralysosomal accumulation of glycogen in multiple organs, manifested primarily in cardiac and skeletal muscles.
The clinical spectrum of GSD-II varies greatly. Muscle specimens from babies affected by the infantile form of GSD-II have less than 1% of normally measured GAA muscle or fibroblast activity levels, and are characterized by prominent cardiac and respiratory muscle involvement. These infants predictably die of cardiac and/or respiratory failure by the age of two; juvenile and adult onset forms of GSD-II are also recognized, the slower progression of muscle pathology in these individuals is attributed to the fact that muscle GAA activities in these patients range from 1 to 10 and 10 to 40% of normal GAA enzyme activity levels, respectively. These relatively milder forms of GSD-II do not manifest lethal cardiac involvement, but nonetheless do suffer from progressive skeletal muscle weakness. These patients eventually succumb to the multiple morbidities associated with respiratory insufficiency/failure. 4, 5 To combat this devastating disease enzyme replacement therapy (ERT) attempts, using recombinant human acid-alpha glucosidase (rhGAA) produced from either transgenic rabbit milk 6, 7 or Chinese hamster ovary rGAA producer cell lines, 8 have demonstrated promising results, with most of the infantile GSD-II patients treated in these trials surviving past the milestone of 1 year. However, the ERT approach is limited by the difficulties of large-scale enzyme production, and the need for repetitive, life-long enzyme injections.
These limitations could, however, be lessened or entirely circumvented by gene therapy approaches. In theory, after a single administration of a gene transfer vector, a longer and sustained GAA expression could be provided from a depot organ successfully transduced with the GAA gene. Secreted GAA from the depot organ could then be taken up by multiple muscle cells simultaneously.
To achieve systemic delivery and correction of multiple muscle groups in adult animal models of GSD-II, our group first developed a gene therapy strategy targeting the liver as an hGAA depot organ. In contrast to nonefficacious intramuscular injections, a simple intravenous injection of a modified adenoviral vector allowed for an extremely efficient transduction of the hGAA gene into the hepatocytes of the tested mice. [9] [10] [11] In this maneuver, the transduced liver is able to secrete large quantities of the hGAA enzyme that is subsequently taken up by multiple muscle groups within the individual animal so treated. Our results have been confirmed in GAA-KO mice and AMD quails, both relevant animal models of GSD-II.
12-14 More importantly, high-level hepatic secretion of hGAA results in a near complete clearance of glycogen in cardiac and skeletal muscles within 12 days of the vector injection. [9] [10] [11] In addition, transgenic GAA-KO mice overexpressing GAA in their liver tissues also demonstrated widespread glycogen clearance, relative to attempts to secrete hGAA transgenically from skeletal muscle. 13 Thus, the liver appears to be an optimal organ for the secretion of GAA enzyme making this enzyme available for muscle cells throughout the body.
Our most recent studies also demonstrated that longterm efficacy of liver targeting of the modified adenoviral vector expressing hGAA could also be achieved. 10 However, although the long-term (46 months) persistence of the vector in mouse liver was verified, the onset of anti-hGAA antibodies within 10 days of vector injection resulted in the lack of detection of plasma hGAA beyond 10 dpi (days postinjection). This prevented us from evaluating the full potential of Admediated transfer of the hGAA gene, since muscles were exposed to exogenous hGAA for only a short period of time. 11 Similarly, in our previous studies of ERT in humans, the onset of anti-rhGAA antibodies have also been correlated with the lack of sustained skeletal muscle efficacy. 15 To both circumvent and prove that production of antihGAA antibodies is a significant problem potentially limiting the efficacy of both ERT or gene therapy approaches to the treatment of GSD-II, we have now developed a new, immune-deficient mouse model of GSD-II. This was achieved by interbreeding GAA-KO mice with severe combined immune-deficient (SCID) mice, generating double knockout, GAA-KO/SCID mice. In the first use of this new animal model of GSD-II, we have examined the short-and long-term efficacy of improved Ad-based, GAA-expressing vectors after intravenous injection of two different dosages into adult, GAA-KO/SCID mice.
Results

Isolation of GAA-KO/SCID mice
Generation of GAAKO/SCID mice was achieved by interbreeding GAA-KO mice 16 with SCID mice. 17, 18 The original GAA-KO mice were produced by targeted disruption of exon 6 of the murine GAA gene by insertion of neomyocin resistance gene (Figure 1a) , the resulting homozygous 6 neo /6 neo GAAKO mice have barely detectable GAA transcripts, and no GAA protein product can be detected in their muscle tissues. 16 Immuno-deficient SCID mice have a spontaneous point mutation in the catalytic subunit of DNA-dependent protein kinase (DNA-PKc) gene (Figure 1b) , resulting in the inability of T-and B-lymphocytes to mature. 17, 18 Interbreeding GAA-KO mice with SCID mice gave rise to F1 double heterozygote mice, designated as GAA+/ ÀSCID+/À. Intercrossing F1 progeny allowed for isolation of double knock out GAA-KO/SCID mice.
To identify positively the GAA-KO/SCID mice, genotypes at both loci were confirmed by PCR analysis and restriction enzyme digestion (SCID mice have a gain of the AluI site in their DNA-PKc gene) ( Figure 1 ). We next confirmed the resultant SCID phenotype of the mice. For example, as shown in Figure 2 , the GAA-KO/ SCID mice failed to produce anti-hGAA antibodies after being intravenously injected with 5 Â 10 10 particles of the [E1-, polymerase-]AdhGAA vector, in contrast to the rapid and robust production of anti-hGAA antibodies previously noted in the parental GAA-KO mice.
The GAA-KO phenotype of the GAA-KO/SCID mice was also confirmed by a number of assays, such as the tests for the plasma and tissue GAA activities, tissue glycogen content and muscle strength; these are summarized in Table 1 . The overall results confirmed that GAA-KO/SCID mice manifest all of the major characteristics of the original GAA-KO mouse, including the lack of significant murine GAA activity, resulting in massive glycogen accumulation in multiple muscle groups. Furthermore, gross inspection of the GAA-KO/SCID mice confirmed that with advancing age, these mice manifested severe pathologies secondary to their muscular dystrophy, including development of scoliosis of the spine and decreased ability to ambulate via the hind limbs.
Persistence of hepatic secreted hGAA in the plasma of GAA-KO/SCID mice We have previously demonstrated that tremendous amounts of hGAA can be hepatically secreted into the circulation after hepatic transduction of GAA-KO liver with an [E1-, polymerase-]AdhGAA vector. Unfortunately, we also observed a rapid loss of detectable hGAA in the plasma of these same mice beyond 10 dpi, this loss was correlated with the onset of high amounts of antihGAA antibody being produced by the GAA-KO mice. Since we had demonstrated that GAA-KO/SCID mice cannot mount anti-hGAA antibody responses, we next wished to analyze what impact the lack of anti-hGAA antibody production had on the efficacy of Ad-mediated hGAA transduction into liver tissues. The lack of antihGAA antibody also allowed us to test the Ad-mediated hGAA gene transfer at a lower dosage.
Long-term correction of GSD-II in GAA-KO/SCID mice F Xu et al Western blots were performed on plasma samples collected from the GAA-KO/SCID mice treated with either 5 Â 10 10 or 6.25 Â 10 9 vector particles at the indicated time points postinjection; the blots demonstrated that the hepatically secreted precursor form of hGAA could be found to persist in the plasma of mice treated with either dose of vector for at least 6 months postinjection (experiment duration) (Figure 3a and b). We note that earlier on evidence of the 76 kDa isoform of hGAA is also detectable in those plasma samples containing the highest concentrations of hGAA. This could be due to the hepatic release of the precursor (from hepatic damage or secretion of this isoform in addition to the mature isoform) and also due to spontaneous degradation by nonspecific proteases in murine blood. The amount of hGAA in the plasma was also quantified (Figure 3c ). This result, combined with our previous studies verifying that [E1-, polymerase-]AdhGAA vector genomes could persistently express hGAA in the livers of GAA-KO mice, 10, 11 confirmed that the lack of detection of hGAA in the plasma of immuno-competent GAA-KO mice after 10 dpi was due primarily to anti-hGAA antibody production. Furthermore, despite the known propensity for the CMV enhancer/promoter element to be silenced in murine liver (both in immune-competent and in SCID mice), 10, 11, 19 hGAA expression occurred throughout the duration of the experiment, allowing for continuous secretion of the precursor form (110 kDa) of hGAA with either high or low dosages of viral vector being injected. Although the persistence of the vector and expression of the hGAA paralleled our previous studies in GAA-KO mice, the lack of anti-hGAA antibodies resulted in our ability to detect hGAA in the plasma for the entire duration of the experiment.
Sustained high levels of hGAA can be detected in multiple tissues of GAA-KO/SCID mice for at least 6 months after [E1-, polymerase-]AdhGAA treatment
Since we have previously shown that the precursor of hepatically secreted hGAA is able to be taken up by various muscle tissues and other organs systemically, [9] [10] [11] and since there is persistent secretion of hGAA precursor in Ad vector-treated GAA-KO/SCID mice as shown in Figure 3 , we speculated whether multiple muscle groups of [E1-,polymerase-]AdhGAA-treated GAA-KO/SCID mice were able to take up the secreted hGAA precursor continuously, which would primarily manifest as a Figure 1 (a) Genotyping of GAA-KO allele. Forward primer (sense primer) p1 at the 3 0 -end of exon 5 of murine GAA and reverse primer (antisense primer) p2 at the 5 0 -end of exon 7 of murine GAA will amplify a 700 bp fragment specific for the normal murine GAA allele. If a GAA-KO allele is present, p1 and p2 primers will span a 2 kb distance because of the insertion of neomyocin-resistant gene in exon 6 of GAA gene, and there will be no PCR product generated from these two primers with the PCR conditions used in this study. Instead, inclusion of a third, forward (sense primer) p3 primer specific for the 3 0 -end of the neomyocin gene, together with the p2 primer will result in PCR amplification of a 450 bp band indicating the knockout allel. Utilizing this genotyping strategy, DNA derived from wild-type mice (w) will generate only one band at 700 bp, in homozygous GAA-KO mice (ko) a single band at 450 bp is detected, while in heterozygous GAA+/À mice (h), both fragments are detected. (b) Genotyping of SCID allele. In SCID mice, a spontaneous mutation at the carboxyl-terminus of the DNA-PKc gene results in the presence of an extra AluI site (A2), in addition to the AluI site (A1) pre-existing in the gene. Primer p1 (sense primer) and p2 (antisense primer) will amplify a 1.3 kb fragment from both SCID allele and wild-type allele. However, after digestion of the PCR products with AluI, the band patterns are different for these two alleles. For the SCID allele, AluI digestion will generate two smaller fragments at 211 and 30 bp, in addition to the 1.1 kb band, due to the presence of an extra AluI site; only one fragment at 241 bp was released in addition to the 1 kb fragment in mice with a normal DNA-PKc allele. Therefore, in wild-type mice (w), a 1.1 kb band and a 241 bp band were detected in homozygous SCID mice (s), a 1.1 kb and a 211 bp band were detected in heterozygous SCID7(h), a 1.1 kb band, a 241 bp and a 211 bp band were detected. Note that the 30 bp band will not normally be detected in this assay. Long-term correction of GSD-II in GAA-KO/SCID mice F Xu et al higher level of hGAA activity in muscle tissues than that previously achieved in similarly treated GAA-KO mice. Therefore, [E1-, polymerase-]AdhGAA-treated GAA-KO/SCID mice were killed at increasing number of times postinjection and their tissue GAA activity levels were determined ( Figure 4 ). The results demonstrated that the GAA activities in skeletal muscle and cardiac muscles were sustained well above levels measured in untreated GAA-KO/SCID mice at all time points tested and with either dose of vector. This was in contrast to our previous results obtained in identically treated GAA-KO mice, which showed marked decreases in GAA muscle activities immediately upon detection of anti-hGAA antibodies. 10 The combination of observations also suggests that sustained secretion of even low levels of hGAA can result in sustained GAA activity levels in multiple muscle tissues, possibly because of continuous uptake of the hepatically secreted hGAA.
Extended duration of glycogen correction in skeletal and cardiac muscle achieved in the absence of anti-hGAA antibodies
In our previous studies, we demonstrated that an intravenous injection of adequate amounts of an [E1-, polymerase-]AdhGAA vector resulted in the crosscorrection of glycogen in multiple muscle tissues. We have also shown that cardiac muscle is most responsive to therapy, with skeletal muscles achieving lesser levels of correction, both with regard to the amount of glycogen cleared and to the duration of time the glycogen content was reduced. 10, 11 With the sustained presence of hGAA in the blood of similarly treated GAA-KO/SCID mice, we hypothesized that this would result in a more beneficial response with regard to glycogen clearance in all muscle groups. In GAA-KO/SCID mice injected with 5 Â 10 10 particles of [E1-, polymerase-]AdhGAA, glycogen content quantification revealed that the glycogen contents of cardiac muscles were completely corrected within 17 days of vector injection, and this was sustained for the entire 6-month duration of the experiment (Figure 5a ). In contrast, in skeletal muscle (quadriceps and diaphragm), glycogen accumulation was never fully corrected, but was nonetheless significantly decreased relative to glycogen levels measured in the same muscles of agematched mock-injected GAA-KO/SCID mice, at all time points tested (Figure 5b and c) . The results suggest that a pool of glycogen present in skeletal muscles appears particles of [E1-, polymerase-]AdhGAA, film exposed for 5 min. Note lack of detection of hGAA in the plasma of GAA-KO mice at 17 dpi with the vector. The '*' in figures and a and b denotes samples in which only 0.2 ml of plasma sample was loaded, because of the extreme amounts of hGAA present at these time points, relative to the later ones. (c) Quantitation of hGAA in plasma of GAA-KO/SCID mice injected with 5 Â 10 10 or 6.25 Â 10 9 particles of [E1-, polymerase-]AdhGAA. Mouse plasma samples from the two different groups of mice were, respectively, electrophoresed together with known amount of rhGAA purified from CHO cells. 8 The gels were transferred onto a nitrocellulose membrane and were probed with an anti-hGAA polyclonal antibody generated in a previously immunized rabbit. Subsequent to ECL detection, the films were analyzed by Scion densitometry image analysis system. The amount of rhGAA represented by each mouse plasma sample was then quantitated as determined in comparison to the rhGAA protein standard curves, (n ¼ 3) and average values for each time point were then plotted against dpi. Note that due to technical issues, the hGAA plasma levels were not determined at 180 days in the low dose injected animals.
Long-term correction of GSD-II in GAA-KO/SCID mice F Xu et al to be either inaccessible or resistant to the continued presence of very high levels of exogenously provided hGAA. In all muscle tissues, we noted that a rapid reduction of glycogen occurred within 17 days of vector injection in the GAA-KO/SCID mice. In addition, the duration of time that significant glycogen decreases were noted were prolonged in all the muscles evaluated, relative to identical [E1-, polymerase-]AdhGAA injections previously performed in age-matched GAA-KO mice. (Figure 5a-c) .
In GAA-KO/SCID mice injected with 6.25 Â 10 9 particles of [E1-, polymerase-]AdhGAA (and despite continued, albeit low levels of hGAA secretion and plasma persistence), significant glycogen reduction was not achieved in the heart until 2.5 and 4 months postinjection; glycogen levels began to rise dramatically beyond this time point (Figure 5a ). Finally, no glycogen reduction was demonstrated in the skeletal muscles of GAA-KO/SCID mice injected with the lower dose of vector at any time point (Figure 5b and c) .
Normalized muscle function after extended glycogen clearance
Our previous research has shown that muscle strength can improve after hGAA ERT in an acid maltase-deficient (AMD) quail model of GSD-II, as well in enzyme-treated Figure 4 Tissue GAA activities. Tissues from GAA-KO/SCID mice injected with 5 Â 10 10 or 6.25 Â 10 9 particles [E1-, polymerase-]AdhGAA (n ¼ 3-7, respectively) at 14, 75, 120 and 180 dpi, noninjected GAA-KO/ SCID mice (n ¼ 3) and wild type (n ¼ 3) were analyzed for GAA activity as described in Materials and methods. Error bars represent the standard deviation for each data set. (a) GAA activity in heart; (b) GAA activity in quadriceps; (c) GAA activity in diaphragm. Note that data for GAA-KO mice injected with 5 Â 10 10 vector particles represents values obtained, generated previously. 10 
Figure 5
Glycogen content of muscles derived from [E1-, polymerase-]AdhGAA-treated GAA-KO/SCID mice at two different dosages. Glycogen level was quantitated as described in Materials and methods. Glycogen levels of injected (n ¼ 3-7 each time point for each group) and uninjected (n ¼ 3) GAA-KO/SCID were compared with wild-type mice. (a) Glycogen level in heart; (b) glycogen level in quadriceps; (c) glycogen level in diaphragm. *Po0.05, # Po0.001 Note that data for GAA-KO mice injected with 5 Â 10 10 vector particles represents values obtained generated previously. 10 Long-term correction of GSD-II in GAA-KO/SCID mice F Xu et al GSD-II patients. 15, 20 Recently, it has been demonstrated that restoration of a single muscle's contractile force can be achieved after intramuscular injection of an AAV vector encoding hGAA. 21 However, the evaluation of overall gross muscle strength has not been reported after attempting gene therapy using viral vectors in GSD-II animal models. This information is critical for analyzing what benefits may be gained in future gene therapy attempts in GSD-II patients, since correction of surrogate markers of the disease (ie GAA levels or glycogen contents) may not necessarily result in improved muscle strength and function. We therefore analyzed whether overall gross muscle strength can be improved after a single injection of the [E1-, polymerase-]AdhGAA vector into GAA-KO/SCID mice, via the use of an accelerating Roto-Rod performance test (indicator of muscle strength, cardiac endurance, as well as coordination), see Figure 6 . Mock-injected GAA-KO/SCID mice demonstrated a profound muscle weakness at all time points analyzed relative to SCID mice, this weakness was also progressive with age. In dramatic contrast, we found that RotoRod endurance was improved significantly within 2 weeks of vector injection in GAA-KO/SCID mice, and this significant improvement was maintained for at least 6 months postinjection ( Figure 6 ). However, mice injected with 6.25 Â 10 9 particles of [E1-, polymerase-]AdhGAA did not show significant improvement in Roto-Rod performance.
Discussion
Our group has previously demonstrated that a single intravenous injection of a modified Ad vector encoding hGAA results in high levels of hepatic secretion of hGAA precursor protein into the circulation. These circulating hGAA precursors can then be taken up (presumably via mannose-6-phosphate receptor-mediated uptake) and correctly delivered into muscle lysosomes. Once in the lysosome, the precursor is cleaved to its active form, resulting in the correction of glycogen storage in multiple affected muscle tissues, this effect was sustained for up to 6 months in the longest experiments. [9] [10] [11] This result has been achieved in two animal models of GSD-II, the GAA-KO mouse and the AMD quail, 10, 14 suggesting that similar levels of efficacy may be achievable in humans as well. However, we have also noted that anti-hGAA antibodies were rapidly elicited (although the absolute amounts could be reduced by use of liver-specific promoter elements 11 ) in the GAA-KO mouse model of Pompe disease (the GAA-KO mouse does neither express any murine GAA RNA nor protein 16 ) after Admediated transfer of the hGAA gene. This has also been noted in neonatal GAA-KO mice treated with an Ad vector expressing hGAA, 22 as well in adult GAA-KO mice treated with AAV vectors expressing hGAA. 23 We have previously correlated the onset of anti-hGAA antibody formation with rapid clearance of precursor hGAA from the bloodstream of treated GAA-KO mice, a problem that we had hypothesized may be preventing us from studying the full potential of our gene therapy strategy.
To prove definitively that the production of antihGAA antibodies significantly impaired the full potential of hGAA gene transfer, we generated a new GAA-KO mouse model that is incapable of generating anti-hGAA antibodies, but yet retains the phenotypic characteristics of the original GAA-KO mouse. This was achieved by interbreeding GAA-KO mice 16 with SCID mice, 17, 18 yielding GAA-KO/SCID mice. Since these mice are immune-deficient, they will not allow the assessment of adaptive (cytotoxic) immune responses to the vector. However, we have shown in previous multiple manuscripts that the identical modified Ad vector used in this report is not subjected to immune-mediated elimination in fully immune-competent GAA-KO mice. The use of GAAKO/SCID mice in this study demonstrated that although we observed a decreasing amount of hGAA expression from the hepatically targeted Ad vector over time (previously demonstrated by us and others to be due to the well-known phenomenon of decreased CMV promoter activity in murine liver 10, 11, 24 ), hGAA precursors were still detectable in the plasma of mice so treated throughout the entire 6-month duration of the experiment, even with doses of vector as low as 6.25 Â 10 9 particles/mouse. Thus this result confirms that the reason we had been unable to previously detect hGAA in the plasma of GAA-KO mice beyond 10 dpi (despite high-level hGAA expression in liver tissues) was primarily due to the presence of large amounts of an anti-hGAA antibody. 11 We found that the lack of anti-hGAA antibodies allowed the hepatically secreted hGAA precursors to be taken up by muscle tissues more efficiently, as reflected by increased amounts of hGAA accumulation within muscle tissues over time. Importantly, these sustained levels of hGAA were not achievable when similar experiments were performed in GAA-KO mice. 10 As a result, the duration of glycogen clearance in muscle tissues of GAA-KO/SCID mice injected with high doses of [E1-, polymerase-]AdhGAA was also prolonged again relative to similar experiments previously performed in GAA-KO mice. Long-term correction of GSD-II in GAA-KO/SCID mice F Xu et al particles of [E1-, polymerase-]AdhGAA, we were also able to demonstrate that heart glycogen levels were normalized at all time points analyzed, in contrast to our previous studies in heart muscles of GAA-KO mice. These latter studies demonstrated that glycogen levels began to increase at the 6 month postinjection time point, despite the same vector dosage. 10 A similar improvement was noted when glycogen contents of quadriceps and diaphragms of the Ad-treated GAA-KO/SCID mice were similarly compared to previous experiments in GAA-KO mice even at the latest time point; however, in both tissues the result was not as robust as that noted in cardiac muscles. Thus, for skeletal muscles, our results demonstrate that sustained plasma levels of rhGAA of at least 1.5 mg/ml can prevent significant reaccumulation of skeletal muscle glycogen over long periods of time (6 months).
In GAA-KO/SCID mice treated with only 6.25 Â 10 9 particles of [E1-, polymerase-]AdhGAA, glycogen reduction was not observed in quadriceps and diaphragm at any time point. However, the persistent, albeit low amounts of exogenous GAA generated by the lower vector doses was able to reduce heart glycogen content at 75 and 120 dpi, a finding that was not observed in similarly treated GAA-KO mice. The results suggest that sustained secretion of rhGAA in a concentration exceeding 0.475 mg/ml plasma can allow for eventual glycogen clearance in heart; however, lower plasma hGAA levels result in reaccumulation of cardiac glycogen content. The differences in glycogen clearance responsiveness to the therapy between cardiac muscle and skeletal muscle was observed previously by our group, 10,11 as well as another group, the latter studying mice transgenically expressing hGAA. 25 Several explanations can be offered as to why cardiac muscle may be more responsive to hGAA than the skeletal muscle, these explanations include known differences in M6P receptor density in the heart relative to skeletal muscle, differences in metabolic rates between the two tissues, fiber type differences between various muscle groups and/or possible differences in the physical structure of glycogen within lysosomes of the two tissues. 26 We also noted another phenomenon, namely, reaccumulation of glycogen in skeletal muscles despite the presence of high GAA activity levels within the same tissues. For example, although significantly decreased skeletal muscle glycogen levels were noted at all time points after vector treatment of the GAA-KO/SCID mice, the glycogen content trended upwards overtime. This dichotomy can be reconciled when one considers that as the mouse ages it is likely that new lysosomes form. These lysosomes will not have access to the same high plasma hGAA levels that older muscle lysosomes encountered shortly after a vector injection, rather these lysosomes are exposed only to low levels of hGAA precursors in the plasma, levels that cannot counteract the persistent rate of glycogen accumulation. With these findings, we conclude that persistent secretion of low amounts of hGAA precursors is enough to prevent glycogen reaccumulation in cardiac muscles that have been cleared of their glycogen, but these low levels are not enough to prevent glycogen accumulation in identically treated skeletal muscles.
In this report, we also note that virally mediated transfer of the hGAA gene can result in rapid physiologic improvement of overall muscle strength, as reflected by the use of an accelerating Roto-Rod performance analysis. The GAA-KO/SCID mice injected with lower dosages of [E1-, polymerase-]AdhGAA particles (6.25 Â 10 9 ) did not show significant improvements relative to mock-injected GAA-KO/SCID, this was positively correlated with no glycogen level decreases in the skeletal muscles of these mice, despite the transient reduction of glycogen in the hearts of these same animals.
In contrast, significant improvements in Roto-Rod performance were noted as early as 2 weeks following high dose vector injection into GAA-KO/SCID mice; furthermore, these improvements were sustained at all time points tested up to 6 months postinjection, thus positively correlating with the significant decreases noted in the skeletal muscles of these same animals. Previous research has shown that the impaired performance of skeletal muscle in GAA-KO mice was attributed to the interruption of the force-generating capacity of the muscle by prominent, glycogen-filled lysosomes. 27 Therefore, it is plausible to conclude that with the rapid clearance of significant amounts of intralysosomal glycogen, interruption of normal muscle fiber contractions can be rapidly overcome (within weeks). Also, this can be achieved even if the total amount of glycogen present in the skeletal muscles is not completely cleared. These results suggest that the residual pool of stored and hGAA inaccessible glycogen is present either in a state, or a subcellular location, which does not hinder recovery of the treated muscle's ability to generate force in response to the clearance of the majority of glycogen that is present in an hGAA accessible state or location. Moreover, improved muscle functions were sustained, despite a slow reaccumulation of glycogen within the same skeletal muscles between 4 and 6 months postvector injection. These results suggest that muscle weakness occurs subsequent to glycogen accumulation (possibly as a result of repeated muscular contractions in the presence of excessive glycogen storage), rather than as a direct result of glycogen accumulation per se.
The use of the GAA-KO/SCID mouse model has verified that the onset of anti-hGAA antibodies may significantly limit the efficacy of therapeutic approaches for GSD-II patients that mount anti-hGAA antibodies to either hGAA expressed from a gene transfer vector, as well as to the recombinant hGAA enzyme. The latter was, in fact, observed in our previous clinical trials utilizing rhGAA in infantile patients. However, as a large number of infantile as well all juvenile or adult onset GSD-II patients would be expected to express a mutated form of hGAA with low GAA activity, 28, 29 these patients would have a low propensity to develop anti-hGAA antibodies and, thus, may be more tolerant of exogenously provided hGAA, either by ERT or gene therapy approaches. Importantly, nearly 50% of adult onset patients actually express a normal GAA protein, but have splice site mutations that decrease overall hGAA expression levels. However, one could still not rule out the possibility that in those patients producing a mutant hGAA protein, antibodies to the normal hGAA (introduced via enzyme replacement or gene therapy) would still be produced and along with that decreased efficacy would be predicted based on the results of this manuscript.
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Materials and methods
Construction of [E1-, polymerase-] adenovirus vectors encoding hGAA
The construction of [E1-, polymerase-] adenovirus encoding full-length human GAA cDNA driven by CMV-based enhancer/promoter has been described.
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The infectious [E1-, polymerase-]AdhGAA virus was isolated, amplified, concentrated and particle numbers determined by sodium dodecyl sulfate (SDS) disruption of CsCl2 purified vector as described previously. 16 Generation of GAA-KO/SCID mice
We bred GAA-KO mice 16 with SCID mice. 17, 18 The F1 generation of the offspring was heterozygous at both the murine GAA and SCID locus, and was designated as GAA-KO+/ÀSCID+/À. F1 mice were intercrossed and all offspring were genotyped to identify GAA-KOÀ/ÀSCIDÀ/À offspring, which we refer to here as GAA-KO/SCID mice. Once identified, GAA-KO/SCID mice were interbred and maintained as a colony.
Genotyping by PCR analysis: Tail specimens were isolated from less than 3-week-old mice (PUREGENE DNA isolation kit, Gentra system) as per the manufacturer's instructions. PCR was performed by using oligonucleotide primers specific for either the murine GAA gene or the SCID locus (Figure 1) .
For genotyping GAA-KO mice: The sense primer p1 (5 0 -CCTTTCTACCTGGCACTGGAGGAC-3 0 ) was designed to be complimentary to sequences located within exon 5 of murine GAA; antisense primer p2 (5 0 -GGACAATG GCGGTCGAGGAGTA-3 0 ) was designed to be complimentary to sequences within exon 7 of murine GAA. The sense primer p3 (5 0 -CCTCGTGCTTTACGGTATCGC-3 0 ) is complementary to sequences within the 3 0 -end of the neomycin resistance gene (inserted to disrupt exon 6 of murine GAA in GAA-KO mice). PCR for genotyping the wild-type GAA or GAA-KO allele was performed on a Biometra thermocycler programmed with the following cycling parameters: initial denaturation at 941C for 4 min, followed by repetitive denaturation at 941C for 30 s, annealing at 601C for 30 s and Taq polymerase extension at 721C for 1 min, for 35 cycles. A final polymerase-mediated extension for 10 min at 721C was followed by storage at 41C. The PCR products were electrophoresed through 2% agarose gels and photographed after ethidium bromide staining.
Genotyping SCID allele: Primer design for SCID allelesense primer p1 (5 0 -GGAAAAGAATTGGTATCCAC-3 0 ); and antisense primer p2 (5 0 -AGTTATAACAGCTGGG TTGGC-3 0 ) were designed to be complementary to sequences at the carboxyl-terminal region of the DNAPKc gene, which is mutated resulting in the SCID allele of this gene gaining an AluI site. PCR was performed with the following cycling parameters: initial denaturation at 941C for 3 min, followed by 40 cycles of denaturation at 941C for 30 s, annealing at 571C for 30 s and Taq polymerase extension at 721C for 2 min, once the cycling was completed, a final extension for 15 min at 721C was followed by storage at 41C. The PCR products were then digested with AluI followed by electrophoresis on 3% agarose gel. The gel was photographed after ethidium bromide staining.
In vivo administration of [E1-, polymerase-]AdhGAA and plasma sampling
All animal procedures were carried out in accordance with the Duke University Institutional Animal Care and Use Committee approved guidelines. GAA-KO/SCID mice (3 months old) were intravenously administrated (via the retroorbital sinus) with either 5 Â 10 10 or 6.25 Â 10 9 particles of [E1-, polymerase-]AdhGAA. Blood samples were obtained at different times postinjection by retroorbital sampling into heparinized capillary tubes, followed by plasma isolation via centrifugation. All plasma samples were kept at À801C.
ELISA detection of plasma anti-hGAA antibody
Recombinant hGAA (5 mg) was coated into each well of a 96-well plate and ELISA was performed to detect antihGAA antibodies as described previously. 10 Western blotting analysis and quantitation of hGAA in mice plasma Each plasma sample was electrophoresed through a denaturing SDS-10% polyacrylamide gel and electrotransferred onto a nitrocellulose membrane. The membrane was blocked with 2% nonfat milk, incubated with a 1:1000 dilution of a rabbit anti-human GAA-specific polyclonal antibody, washed and probed with a 1:5000 dilution of a horse radish peroxidase-linked anti-rabbit IgG derived from donkey (Amersham Pharmacia, Piscataway, NJ, USA) and visualized by the enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia, Piscataway, NJ, USA).
For quantitation of hGAA in plasma samples, a known amount of rhGAA was also loaded in the same gels with the experimental plasma samples to generate standard curves for rhGAA concentration. Western blotting was then performed as described previously. The amount of hGAA present in each plasma sample lane then was determined in comparison to the rhGAA standards, via use of the Scion densitometry image analysis system.
Detection of plasma/tissue GAA activities and tissue glycogen content
For plasma GAA activity detection, plasma samples at different time points were evaluated. For tissue GAA measurements, the respective tissues were removed from treated or control mice at different time points, snapfrozen in liquid nitrogen, homogenized, sonicated and insoluble proteins were removed by centrifugation. The protein concentrations of the clarified suspensions were quantified via Bradford assay. GAA activity in the plasma or tissues, and glycogen content of tissues, were determined as described previously. Two-tailed homoscedastic Student's t-tests were utilized to determine P-values after comparing GAA activity and glycogen content between control and viral vector-injected animal-derived tissues.
Roto-Rod performance test
All mice were tested at different time points on a RotoRod device (UGO, Basile, Italy). Each mouse was conditioned to the device by performance of two, 30-s attempts on the rod at a constant speed of 4 revolutions per minute. Following the conditioning phase, each mouse was then placed on the rod and timed for their Long-term correction of GSD-II in GAA-KO/SCID mice F Xu et al duration to remain on the rod as it accelerated to a maximal rate of 40 revolutions per minute. This was repeated and the average of the runs was used as the final endurance time for each mouse. At each time point, up to 10 mice were tested, and the average performance of all mice at each time point was plotted against days postvector injection. Two-tailed homoscedastic Student's t-tests were utilized to determine the significant difference in accelerating Roto-Rod performance.
